J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?
J&J JNJ stock has risen more than 6% in the past month. The reason behind the increase was a strong-than-expected fourth-quarter earnings report and an optimistic outlook for the Innovative Medicine segment despite several headwinds,
Let's understand the company's strengths and weaknesses to better analyze how to play J&J's stock amid the recent price increase.
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals and medical devices divisions. It has more than 275 subsidiaries, which clearly means that the business is extremely well-diversified. Its diversification helps it to withstand economic cycles more effectively. J&J has 26 platforms with more than $1 billion in annual sales. Meanwhile, J&J has one of the largest R&D budgets among pharma companies.
J&J separated its Consumer Health business into a newly listed company called Kenvue (KVUE) in 2023, which allowed it to focus on its core pharmaceutical and medical device business.
J&J's Innovative Medicine unit is showing a growing trend. The segment's sales rose 5.8% in 2024 on an organic basis. In 2025, J&J expects growth in the Innovative Medicine segment despite the loss of exclusivity ('LOE') for its multi-billion-dollar product Stelara, the approximately $2 billion negative impact of the Part D redesign and the greater impact of currency fluctuations. Growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato and Erleada, as well as new drugs like Carvykti, Tecvayli and Talvey and new indications for Tremfya and Rybrevant.
J&J expects to generate more than $57 billion in sales in the Innovative Medicines segment in 2025. It expects the Innovative Medicine business to grow 5% to 7% from 2025 to 2030.
Moreover, J&J believes 10 of its new Innovative Medicine products, including new cancer drugs like Talvey and Tecvayli, and pipeline candidates like nipocalimab and icotrokinra (JNJ-2113), have the potential to deliver peak non-risk-adjusted operational sales of $5 billion.
J&J lost U.S. patent exclusivity of its blockbuster drug, Stelara, in 2025. Stelara generated sales of $10.36 billion in 2024. The launch of generics is expected to significantly erode the drug's sales and hurt J&J's sales and profits in 2025. A biosimilar version of Stelara was launched in certain European markets for certain indications in July 2024. Several biosimilar versions of Stelara are expected to be launched in the United States in 2025. Amgen AMGN launched the first Stelara biosimilar, Wezlana, in January 2025. Stelara biosimilar competition is expected to accelerate throughout 2025 as the number of biosimilar entrants increases. Stelara's loss of exclusivity negatively impacted sales growth by 290 basis points worldwide and 720 basis points in Europe in the fourth quarter. The impact is expected to be higher in 2025.
In addition, sales in 2025 will be hurt by greater Fx impact and approximately $2 billion impact from the Medicare Part D redesign.
Sales in J&J's MedTech business are facing continued headwinds in the Asia Pacific, specifically in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program and the anticorruption campaign. VBP is a government-driven cost-containment effort in China. J&J does not expect any improvement in its business in the Asia Pacific region, specifically in China, in 2025. Competitive pressure is also hurting sales growth in some MedTech businesses, such as PFA ablation catheters in U.S. electrophysiology. It expects continued impacts from VBP issues in China in 2025 as VBP continues to expand across provinces and products.
Nonetheless, though issues in China are hurting sales, J&J is successfully shifting its portfolio to high-innovation, high-growth markets, particularly in Cardiovascular. With the recent acquisitions of Shockwave in 2024 and Abiomed in 2022, J&J has become a category leader in four of the largest and highest-growth cardiovascular intervention MedTech markets.
J&J expects the overall MedTech market to grow in the range of 5-7% between 2022 and 2027.
J&J faces more than 62,000 lawsuits for its talc-based products, primarily baby powders. The lawsuits allege that its talc products contain asbestos, which caused many women to develop ovarian cancer. J&J insists that its talc-based products are safe and do not cause cancer. The company permanently discontinued the sales of its talc-based Johnson's Baby Powder.
J&J failed twice in its attempts to seek bankruptcy to fully resolve these thousands of lawsuits related to its talc products.
However, in 2024, J&J made strong progress toward resolving the talc litigation. In May 2024, the company proposed a new plan committing to pay claimants approximately $6.5 billion nominally over 25 years, which could resolve 99.75% of all pending talc lawsuits against it.
In September, J&J, via another subsidiary called Red River Talc, filed for voluntary bankruptcy (in Texas) for the third time after it received the support of around 83% of current claimants for the proposed bankruptcy plan. Red River also increased its settlement commitment by $1.75 billion to approximately $8 billion. The talc bankruptcy confirmation hearing is expected to take place in 2025.
J&J's stock has outperformed the industry in the past six months. The stock has lost 2.2% in the past six months compared with 11.3% decline of the industry. The stock is also trading above its 200-day and 50-day moving averages.
Image Source: Zacks Investment Research
From a valuation standpoint, J&J appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company's shares currently trade at 14.67 forward earnings, lower than 16.39 for the industry and the stock's 5-year mean of 15.96.
JNJ Stock Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has risen from $10.55 per share to $10.58 per share over the past 30 days, while that for 2026 has declined from $11.16 per share to $11.06 per share over the same timeframe.
Image Source: Zacks Investment Research
J&J's Innovative Medicines segment is showing a growth trend. The company has an interesting R&D pipeline that can generate innovative products and drive its growth further. J&J has been on an acquisition spree lately. It completed the acquisitions of Shockwave and V-Wave in MedTech and Ambrx, Proteologix and NM26 bispecific antibody in Innovative Medicine in 2024, which strengthened its pipeline. Continuing the M&A momentum, last month, J&J announced a definitive agreement to acquire Intra-Cellular Therapies ITCI for approximately $14.6 billion, which will strengthen its presence in the neurological and psychiatric drug market.
However, the softness in the MedTech unit, Stelara patent cliff and the potential impact of Part D redesign will be big headwinds in 2025. It remains to be seen how the company navigates them in 2025.
Those who already own this Zacks Rank #3 (Hold) company's shares may stay invested for some time as the visibility for a potential resolution of the talc lawsuits has improved, and J&J looks optimistic about a better performance in 2025.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
Amgen Inc. (AMGN) : Free Stock Analysis Report
Intra-Cellular Therapies Inc. (ITCI) : Free Stock Analysis Report
Kenvue Inc. (KVUE) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Springfield organization helps make homeownership possible
DAYTON, Ohio (WDTN) — It's National Homeownership Month, and one local organization is helping turn people's dreams into reality. On Monday, the Neighborhood Housing Partnership of Greater Springfield celebrated seven new home builds along Clifton Avenue. The NHP has been in Springfield since 2002, but it's because of assistance from area agencies that the programs they offer continue to thrive. 'We care about people and getting them into home ownership or whatever their goals are,' said Kerri Brammer, NHP Home Ownership Center manager. Lining the block of a neighborhood across the street from John Legend Theatre, dreams are coming true for seven Springfield families. 'It's very exciting. It's taken us a while,' said Brammer. 'It takes a lot of funding, a lot of partnerships to get this far.' None of this work would be possible without the city of Springfield helping set the foundation, alongside a property group building these houses from scratch. 'One of the great things about homeownership is that it helps move people out of the poverty cycle and into building wealth,' said Rachel Goff, NHP executive director. The NHP of Greater Springfield is breaking down barriers one house at a time, paving the way for people considered a part of the low-income population. A realtor and board member with NHP says while the process can be tough, it's worth it — especially if it's your first time buying a home. 'The feeling is very exhilarating only because, you know, sometimes people get defeated, they want to give up, they don't want to keep pushing forward,' said Tyler Hicks, NHP board of directors member. 'But at the same time, there's still that glimmer of hope.' Torrance Johnson is just one example of someone who used the resources offered by NHP to purchase his first home. 'You got that desire to get a house, they could actually get you into a house,' said Torrance Johnson, homeowner through NHP. 'Because they got programs to actually help you out, to actually obtain that home within a beautiful budget.' Johnson says he's grateful to have a brand new house, and hopes to see more neighbors move in soon. 'I hope they appreciate it as much as I appreciate mine,' said Johnson. After starting new builds on Clifton Avenue in 2008, the NHP has grown its portfolio to nearly 20 houses on that block alone. If you're interested in buying, NHP says the best thing to do is get the process started now. To learn more about NHP of Greater Springfield's resources, visit their website. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
6 hours ago
- Yahoo
Former Texas Star Collin Johnson Makes Major Personal Announcement
Former Texas Star Collin Johnson Makes Major Personal Announcement originally appeared on Athlon Sports. Former Texas Longhorn wide receiver Collin Johnson recently announced a significant academic achievement, revealing that he completed the Harvard Business School Executive Program. The update marks a significant step in his post-football career, with a focus on expanding his impact beyond the field. Collin Johnson Completes Harvard Program in Media and Business Johnson shared the announcement in a post on Instagram, standing outside the iconic Harvard Business School campus. In his caption, he wrote: Advertisement 'Just completed the Harvard Business School Executive Program focused on Business, Entertainment, Media, and Sports!' Jan 1, 2019; New Orleans, LA, USA; Texas Longhorns wide receiver Collin Johnson (9) runs against Georgia Bulldogs defensive back Eric Stokes (27) after a catch in the second half of the 2019 Sugar Bowl at the Mercedes-Benz Superdome. The Texas Longhorns won 28-21. Chuck Cook-USA TODAY Sports Johnson's inclusion in the program suggests a growing interest in areas that connect athletics with business and entertainment sectors. Johnson's Next Steps Beyond Football The former Longhorn standout was congratulated by many. Someone wrote, 'Congrats to former Longhorn @Call_In_Johnson.' Johnson played college football at Texas from 2016 to 2019. He stood out for his size and reliable hands as a wide receiver. Now, he is making a different kind of move, this time off the field. His shift from football to higher education follows a growing trend. More athletes are preparing early for life after sports. Johnson's completion of the Harvard Business School Executive Program is a major personal milestone. It could also open doors in business, media, or leadership roles. Advertisement His message shows a clear drive to keep learning. He wants to grow in areas that connect with his playing background. It's not yet clear what his exact next step will be. But this decision signals he's gearing up for a second act in industries that align with what he already knows. For now, Johnson's focus appears clear. Developing new skills in spaces where sports, business, and media come together. Related: Former Texas Star Collin Johnson Makes Major Personal Announcement Related: Do the Bears Have a Gem of a Pass-Catcher in Collin Johnson? This story was originally reported by Athlon Sports on Jun 9, 2025, where it first appeared.
Yahoo
6 hours ago
- Yahoo
GOP lawmakers uneasy about package to codify DOGE cuts ahead of House vote this week
Multiple Republican lawmakers are voicing concerns about backing a high-profile measure later this week to codify Elon Musk's DOGE cuts – raising questions about whether it can pass the House at all. Two Republicans – Reps. Mark Amodei of Nevada and Nicole Malliotakis of New York – separately told CNN they have concerns with the White House's push to defund the Corporation for Public Broadcasting. 'Still mulling,' Amodei said when asked if he would support the package of cuts. 'The impact on local PBS stations appears to be significant.' Other Republicans have heartburn about how it could cut the Bush-era program, PEPFAR, devoted to fighting HIV and AIDS globally. 'If it cuts PEPFAR like they're saying it is, that's not good,' GOP Rep. Don Bacon of Nebraska told CNN last week. House GOP leaders plan to put the package of cuts, totaling $9.4 billion, on the floor as soon as Thursday, according to two people familiar with the plans. But Speaker Mike Johnson will need near unanimity in his conference for the package to pass the House, where he can only lose three votes. Johnson said on Monday that he's 'working on' getting enough votes for the Department of Government Efficiency spending cuts package he hopes to bring to the floor this week. 'The only concern I heard initially was some wanted a little more specificity and detail on what was in the package,' Johnson continued. Asked how he would persuade members that wanted more specificity in the package, Johnson replied, 'I'm gathering up all their questions and we'll try to get them all answered. I mean, that's what we do in every piece of legislation.' If it can survive the House, it will face major obstacles in the Senate. Sen. Susan Collins of Maine told CNN on Monday that she has major misgivings about the global health cuts, including PEPFAR. 'I think we can change it. We're still figuring out what the set rules are,' Collins said. The White House sent its long-awaited spending cuts request to Congress as it seeks to formalize a slew of DOGE slashes to federal funding. The $9.4 billion package – known as 'rescissions' on Capitol Hill – would claw back previously appropriated government funding. The move to cancel the funding through Congress would insulate the administration from legal challenges related to its cuts to federal funding. Johnson said on Monday, 'We'd like to do multiple rescissions packages, and this first one I'm sure will be successful.' This initial request, however, is far more limited in scope than the more than $1 trillion in spending cuts that DOGE has promised. The lengthy time it took the White House to send over a first round of cuts underscores the uphill battle for even a Republican-led Congress to codify DOGE's work. CNN's Molly English contributed to this report.
